drugset / Trial / NCT05211050

Effect of Sumatriptan on Levcromakalim-Induced Symptoms in Individuals With Migraine

NCT05211050

Completed 24 enrolled Danish Headache Center
RandomizedCrossoverQuadruple-blindOther

Summary

The study aims to explore the effects of Sumatriptan on Levcromakalim-induced migraine in individuals with migraine without aura.

Timeline

Start
2022-03-15
Primary completion
2023-11-05
Completion
2023-11-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Sumatriptan Unknown 4 mg
Comparator Levcromakalim Small molecule 1 mg Intravenous

Indications